Claims
What was said, typed and attributed. Statements as reported by the cited publishers — not verified by DecisionGateway.
Follow via RSS — the 30 newest claims in any reader, no account needed.
Claims by
statementSIM0725 was independently developed by the company.先聲藥業集團statementSIM0725 is a long-acting antagonistic monoclonal antibody targeting the interleukin-2 receptor beta chain (CD122).先聲藥業集團statementSIM0725 is intended for the treatment of autoimmune diseases.先聲藥業集團investigationSIM0725 has been approved by the National Medical Products Administration to conduct clinical trials in China.先聲藥業集團
4 of 4